What is HC Wainwright’s Forecast for CMPS FY2026 Earnings?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Stock analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Compass Pathways in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.36) per share for the year, up from their previous estimate of ($2.00). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ FY2027 earnings at ($0.72) EPS, FY2028 earnings at $1.56 EPS and FY2029 earnings at $3.69 EPS.

A number of other equities research analysts have also commented on CMPS. Royal Bank Of Canada increased their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Canaccord Genuity Group upped their target price on shares of Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Morgan Stanley increased their price target on shares of Compass Pathways from $11.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Finally, Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.13.

Compass Pathways Stock Performance

Shares of NASDAQ:CMPS opened at $6.58 on Thursday. The business has a fifty day moving average of $6.98 and a 200-day moving average of $6.15. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. Compass Pathways has a twelve month low of $2.25 and a twelve month high of $8.90. The firm has a market cap of $631.81 million, a PE ratio of -2.42 and a beta of 1.90.

Institutional Investors Weigh In On Compass Pathways

Several institutional investors have recently added to or reduced their stakes in CMPS. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the 4th quarter valued at about $38,000. Advisory Services Network LLC acquired a new stake in Compass Pathways in the 3rd quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd bought a new stake in Compass Pathways in the 4th quarter valued at approximately $47,000. China Universal Asset Management Co. Ltd. boosted its position in Compass Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock worth $51,000 after acquiring an additional 5,817 shares during the last quarter. Finally, BIT Capital GmbH acquired a new stake in shares of Compass Pathways in the third quarter valued at approximately $54,000. 46.19% of the stock is owned by institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.